Atea Financial Statements From 2010 to 2024

AVIR Stock  USD 3.30  0.10  2.94%   
Atea Pharmaceuticals financial statements provide useful quarterly and yearly information to potential Atea Pharmaceuticals investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Atea Pharmaceuticals financial statements helps investors assess Atea Pharmaceuticals' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Atea Pharmaceuticals' valuation are summarized below:
Gross Profit
-81.9 M
Market Capitalization
287.2 M
Enterprise Value Revenue
58.974
Revenue
192.2 M
Earnings Share
(2.07)
There are over one hundred nineteen available fundamental signals for Atea Pharmaceuticals, which can be analyzed over time and compared to other ratios. Investors and active traders are advised to validate Atea Pharmaceuticals' prevailing fundamental performance against the performance between 2010 and 2024 to make sure the trends are evolving in the right direction. As of 11/26/2024, Market Cap is likely to drop to about 241.6 M. In addition to that, Enterprise Value is likely to drop to about 107.3 M

Atea Pharmaceuticals Total Revenue

192.18 Million

Check Atea Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Atea Pharmaceuticals' main balance sheet or income statement drivers, such as Net Interest Income of 30.7 M, Interest Income of 30.7 M or Depreciation And Amortization of 436.8 K, as well as many indicators such as Price To Sales Ratio of 2.3, Dividend Yield of 0.0 or PTB Ratio of 0.48. Atea financial statements analysis is a perfect complement when working with Atea Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Atea Pharmaceuticals Correlation against competitors.
To learn how to invest in Atea Stock, please use our How to Invest in Atea Pharmaceuticals guide.

Atea Pharmaceuticals Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets541.8 M595 M251.7 M
Slightly volatile
Other Current Liabilities20 M27.4 M9.3 M
Slightly volatile
Total Current Liabilities57 M32.4 M33.3 M
Slightly volatile
Other Liabilities6.3 MM1.7 M
Slightly volatile
Property Plant And Equipment Net3.3 M3.1 M740 K
Slightly volatile
Accounts Payable2.3 M4.3 M1.2 M
Slightly volatile
Cash136.6 M143.8 M191.6 M
Slightly volatile
Non Current Assets Total4.7 M4.5 M1.2 M
Slightly volatile
Non Currrent Assets Other1.5 M1.4 M373.5 K
Slightly volatile
Other Assets0.951.0223.3 K
Slightly volatile
Cash And Short Term Investments530.8 M578.1 M246.8 M
Slightly volatile
Common Stock Total Equity50.9 K95.5 K33 K
Slightly volatile
Common Stock Shares Outstanding85.7 M83.4 M62.1 M
Slightly volatile
Liabilities And Stockholders Equity541.8 M595 M251.7 M
Slightly volatile
Non Current Liabilities TotalM7.4 M48 M
Slightly volatile
Other Current Assets10.7 M12.3 M4.7 M
Slightly volatile
Other Stockholder Equity658.3 M750.7 M285.4 M
Slightly volatile
Total Liabilities78.3 M39.8 M82.2 M
Very volatile
Property Plant And Equipment GrossM3.8 M863.1 K
Slightly volatile
Total Current Assets539.7 M590.5 M250.7 M
Slightly volatile
Capital Stock64.3 K95.5 K33.9 K
Slightly volatile
Non Current Liabilities Other7.2 M6.8 M1.8 M
Slightly volatile
Net Working Capital461.3 M558.1 M216.1 M
Slightly volatile
Common Stock64.3 K95.5 K33.9 K
Slightly volatile
Property Plant Equipment4.9 M4.7 M957.4 K
Slightly volatile
Net Receivables4.7 M5.2 M5.7 M
Slightly volatile
Capital Surpluse696.8 M752.1 M633.2 M
Slightly volatile
Short and Long Term Debt Total2.1 M2.4 M665.9 K
Slightly volatile
Capital Lease Obligations2.1 M2.4 M665.9 K
Slightly volatile

Atea Pharmaceuticals Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Net Interest Income30.7 M29.2 MM
Slightly volatile
Interest Income30.7 M29.2 MM
Slightly volatile
Depreciation And Amortization436.8 K416 K88.7 K
Slightly volatile
Selling General Administrative31.8 M49.9 M15.2 M
Slightly volatile
Other Operating Expenses108.5 M164.2 M51.7 M
Slightly volatile
Research Development80.1 M132.8 M38 M
Slightly volatile
Cost Of Revenue73.6 M70.1 M9.6 M
Slightly volatile
Total Operating Expenses95.6 M94.1 M46.2 M
Slightly volatile
Reconciled Depreciation436.8 K416 K88.7 K
Slightly volatile
Total Other Income Expense Net30.7 M29.2 MM
Slightly volatile
Non Operating Income Net Other162.8 K244.9 K116.5 K
Slightly volatile
Selling And Marketing Expenses39.6 M44.5 M48.5 M
Slightly volatile

Atea Pharmaceuticals Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation26.4 M49.4 M11.6 M
Slightly volatile
Begin Period Cash Flow343.7 M188.7 M155.9 M
Slightly volatile
Depreciation436.8 K416 K88.7 K
Slightly volatile
Issuance Of Capital Stock196.7 K207 K59.2 M
Pretty Stable
End Period Cash Flow136.6 M143.8 M161.1 M
Slightly volatile
Change To Netincome49.8 M47.4 M12.7 M
Slightly volatile
Sale Purchase Of Stock1.3 M1.3 M390.3 M
Slightly volatile
Change To Inventory4.1 M4.6 MM
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio2.32.4252.5307
Slightly volatile
Days Sales Outstanding34.9139.2842.7697
Slightly volatile
Stock Based Compensation To Revenue0.140.130.1455
Slightly volatile
Capex To Depreciation7.066.731.9493
Slightly volatile
Payables Turnover17.3116.4842.3094
Slightly volatile
Sales General And Administrative To Revenue0.140.150.363
Slightly volatile
Research And Ddevelopement To Revenue0.690.550.7195
Slightly volatile
Capex To Revenue0.00.04.0E-4
Slightly volatile
Cash Per Share5.436.93263.4669
Slightly volatile
Days Payables Outstanding21.0422.142712 K
Very volatile
Current Ratio13.2118.237417.9973
Pretty Stable
Receivables Turnover6.697.538.1963
Slightly volatile
Graham Number16.4115.62795.7753
Slightly volatile
Debt To Equity9.0E-40.0010.0011
Slightly volatile
Capex Per Share0.02210.0210.0046
Slightly volatile
Revenue Per Share1.943.821.3823
Slightly volatile
Interest Debt Per Share0.110.130.1396
Slightly volatile
Debt To Assets9.0E-40.0010.0011
Slightly volatile
Days Of Payables Outstanding21.0422.142712 K
Very volatile
Ebt Per Ebit1.030.8220.9553
Very volatile
Total Debt To Capitalization9.0E-40.0010.0011
Slightly volatile
Debt Equity Ratio9.0E-40.0010.0011
Slightly volatile
Quick Ratio13.2118.237417.9973
Pretty Stable
Net Income Per E B T0.771.00750.947
Slightly volatile
Cash Ratio4.224.442316.3377
Slightly volatile
Days Of Sales Outstanding34.9139.2842.7697
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.80.910.9827
Slightly volatile
Fixed Asset Turnover14.4 K13.7 K4.7 K
Slightly volatile
Debt Ratio9.0E-40.0010.0011
Slightly volatile
Price Sales Ratio2.32.4252.5307
Slightly volatile
Asset Turnover0.210.410.1432
Slightly volatile
Gross Profit Margin0.80.90.9797
Slightly volatile
Operating Cycle34.9139.2842.7697
Slightly volatile

Atea Pharmaceuticals Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap241.6 M254.3 M1.4 B
Slightly volatile

Atea Fundamental Market Drivers

Cash And Short Term Investments578.1 M

Atea Upcoming Events

27th of February 2024
Upcoming Quarterly Report
View
13th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
27th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Atea Pharmaceuticals Financial Statements

Atea Pharmaceuticals shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Atea Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Atea Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Atea Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue(0.90)(0.85)
Cost Of Revenue70.1 M73.6 M
Stock Based Compensation To Revenue 0.13  0.14 
Sales General And Administrative To Revenue 0.15  0.14 
Research And Ddevelopement To Revenue 0.55  0.69 
Revenue Per Share 3.82  1.94 
Ebit Per Revenue 0.35  0.37 

Pair Trading with Atea Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Atea Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Atea Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving together with Atea Stock

  0.7VALN Valneva SE ADRPairCorr
  0.62VCNX VaccinexPairCorr

Moving against Atea Stock

  0.73BMY Bristol Myers Squibb Sell-off TrendPairCorr
  0.61EWTX Edgewise TherapeuticsPairCorr
  0.6GILD Gilead SciencesPairCorr
  0.48KZR Kezar Life SciencesPairCorr
  0.38VRDN Viridian Therapeutics Buyout TrendPairCorr
The ability to find closely correlated positions to Atea Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Atea Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Atea Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Atea Pharmaceuticals to buy it.
The correlation of Atea Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Atea Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Atea Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Atea Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for Atea Stock Analysis

When running Atea Pharmaceuticals' price analysis, check to measure Atea Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Atea Pharmaceuticals is operating at the current time. Most of Atea Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Atea Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Atea Pharmaceuticals' price. Additionally, you may evaluate how the addition of Atea Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.